Mild corticosteroids may reduce Sjögren’s inflammation
A mild topical corticosteroid may be effective in treating the symptoms of Sjögren’s disease without causing the adverse effects associated with higher-dose steroids. Findings from a pilot study also suggest that ocular surface metrology is useful in evaluating the effects of the steroid.
Reviewed by Ranjini Kottaiyan, OD, MBA
Take-home message: A mild topical corticosteroid may be effective in treating the symptoms of Sjögren’s disease without causing the adverse effects associated with higher-dose steroids. Findings from a pilot study also suggest that ocular surface metrology is useful in evaluating the effects of the steroid.
Rochester, NY-A mild topical corticosteroid could be effective in treating the symptoms of Sjögren’s syndrome by reducing the inflammatory tear cytokines and the rate of evaporation, suggest findings from a small pilot study.
Visit:
Ocular surface metrology performed with tools-such as wavefront sensing and thermal imaging-appear to be effective in analyzing the effects of treatment, said Ranjini Kottaiyan, OD, MBA, lead researcher, Ocular Surface Laboratory, Flaum Eye Institute, University of Rochester, Rochester, NY.
Corticosteroids have been used to treat dry eye symptoms of Sjögren’s syndrome. However, the risk of adverse effects, such as increased IOP and cataract formation after prolonged use, has prompted interest in a lower strength steroid, such as loteprednol etabonate ophthalmic suspension 0.5% (Lotemax, Bausch + Lomb).
Related:
Loteprednol was administered QID for 2 weeks in this study, which enrolled 10 subjects (20 eyes) with Sjögren’s syndrome.
Internal server error